High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes

[11] Weng JP(2013)Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians Diabetes Care 36 145-322

[12] Jia WP(2011)High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects Diabetes Care 34 2113-1844

[13] Saeedi P(2020)Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial Acta Diabetol 57 991-257

[14] Petersohn I(2009)Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 773-363

[15] Salpea P(2016)Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 375 311-1294

[16] Malanda B(2016)Semaglutide and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 375 1834-2325

[17] Karuranga S(2016)Markers of beta-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes Diabetes Care 39 250-274

[18] Unwin N(2016)Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus Diabetes Metab 42 358-112

[19] Palmer SC(2012)Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance PLoS ONE 7 e48392-2635

[20] Mavridis D(2015)Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study J Diabetes Compl 29 1287-148

[11] Weng JP(2013)Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians Diabetes Care 36 145-322

[12] Jia WP(2011)High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects Diabetes Care 34 2113-1844

[13] Saeedi P(2020)Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial Acta Diabetol 57 991-257

[14] Petersohn I(2009)Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 773-363

[15] Salpea P(2016)Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 375 311-1294

[16] Malanda B(2016)Semaglutide and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 375 1834-2325

[17] Karuranga S(2016)Markers of beta-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes Diabetes Care 39 250-274

[18] Unwin N(2016)Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus Diabetes Metab 42 358-112

[19] Palmer SC(2012)Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance PLoS ONE 7 e48392-2635

[20] Mavridis D(2015)Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study J Diabetes Compl 29 1287-148